Introduction

Antibacterial prescription patterns within the hospital setting are distinct from those followed within the community. Increasing age and severity of infection alongside concerns regarding pathogen resistance make the hospital segment a keen focus area for many manufacturers. However, these factors also present unique and tough challenges that now threaten future investment in this field. 

Scope

Detailed segmentation of the hospital antibacterial market, including annual sales by country, product and type of infection.  

In depth strategic analyses focusing on pricing and reimbursement, successful product characteristics and optimal positioning and promotion.  

Accompanying future focus report incorporates market evaluations for 2008, including sales forecasts by country, product and type of infection. 

Additional epidemiology database encompassing more that 1000 data-points relating to incidence of key infections across the seven major markets. 

Report Highlights

The hospital antibacterial market is currently valued at $8 billion, which represents approximately 30% of total antibacterial sales. Of these sales, $1.4 billion (22%) can be attributed to the treatment of respiratory tract infections, a figure that will rise to $2.0 billion (28%) by 2008. 

While overall antibacterial sales are forecast to be relatively flat to 2008 (CAGR 2002-2008 – 0.6%), hospital sales are expected to increase more rapidly (CAGR 2002-2008 – 2.0%). The majority of this growth will be driven by uptake of novel or generic products, while current leaders will face tough challenges to maintain sales. 

Responsibility for the care and treatment of the patient is increasingly being shared between a variety of health professionals. As a result, companies marketing antibacterials may need to re-evaluate promotional strategy to incorporate a selection of physicians, pharmacists and microbiologists.

Reasons to Purchase

Gain expert-led insight into factors that define the hospital sector, such as drug-resistance, infection control and cost-containment.  

Understand drivers of prescription choice, including product characteristics, treatment guidelines and information networks within a clinical setting 

Support R&D prioritization decisions through clear understanding of hospital market segmentation by product and type of infection. 

November 2003, 332 pages 

Publisher: Datamonitor Infectious Diseases Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Infectious_Diseases.html#a334